Pages that link to "Q34022149"
Jump to navigation
Jump to search
The following pages link to Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect (Q34022149):
Displaying 50 items.
- Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations (Q21560973) (← links)
- Hepatitis C virus core-derived peptides inhibit genotype 1b viral genome replication via interaction with DDX3X (Q24300748) (← links)
- Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core (Q24318808) (← links)
- A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production (Q24320237) (← links)
- Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides (Q24564462) (← links)
- Hepatitis C virus protease inhibitor-resistance mutations: our experience and review (Q24628717) (← links)
- Management of HCV-Associated Liver Cirrhosis (Q26740320) (← links)
- Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C (Q26745769) (← links)
- Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection (Q26746563) (← links)
- Recent Advances in Antiviral Therapy for Chronic Hepatitis C (Q26750476) (← links)
- Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life (Q26750628) (← links)
- Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications (Q26777408) (← links)
- The New Era of Interferon-Free Treatment of Chronic Hepatitis C (Q26777716) (← links)
- Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals (Q26782033) (← links)
- HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy (Q26782405) (← links)
- Finally sofosbuvir: an oral anti-HCV drug with wide performance capability (Q26822400) (← links)
- Viral kinetic modeling: state of the art (Q26824655) (← links)
- Oral antiviral therapies for chronic hepatitis C infection (Q26830426) (← links)
- Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy (Q26853500) (← links)
- Modelling hepatitis C therapy--predicting effects of treatment (Q26864673) (← links)
- Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function (Q26991855) (← links)
- Emerging therapies for the treatment of hepatitis C (Q27003319) (← links)
- Daclatasvir: potential role in hepatitis C (Q27012741) (← links)
- Spatiotemporal analysis of hepatitis C virus infection (Q27320822) (← links)
- Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition (Q27335920) (← links)
- Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase (Q27676021) (← links)
- A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase Inhibitors (Q27676763) (← links)
- The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors (Q27682272) (← links)
- New insights into HCV replication: potential antiviral targets (Q27691438) (← links)
- Hepatitis C Virus and Antiviral Drug Resistance (Q28067295) (← links)
- Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis (Q28070260) (← links)
- Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis (Q28077287) (← links)
- Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C (Q28080225) (← links)
- Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges (Q28272678) (← links)
- A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry (Q28475468) (← links)
- Direct Binding of a Hepatitis C Virus Inhibitor to the Viral Capsid Protein (Q28481306) (← links)
- Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity (Q28481438) (← links)
- Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response (Q28481489) (← links)
- A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity (Q28537708) (← links)
- HCV core residues critical for infectivity are also involved in core-NS5A complex formation (Q28539751) (← links)
- Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins (Q28546101) (← links)
- Applications of computer-aided approaches in the development of hepatitis C antiviral agents (Q30238530) (← links)
- Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment (Q30240274) (← links)
- NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. (Q30352718) (← links)
- Daclatasvir: A Review in Chronic Hepatitis C. (Q30392100) (← links)
- Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein (Q30421625) (← links)
- Pharmacokinetics of new oral hepatitis C antiviral drugs (Q30422746) (← links)
- Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration (Q30685690) (← links)
- Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort (Q33557819) (← links)
- Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. (Q33622970) (← links)